Streetbeat News

Stock Prices

CYBN

Cybin is set to commence its Phase 3 pivotal program for CYB003 in late summer, following a Type B Initial Breakthrough Therapy meeting with the FDA. The company has selected 30 clinical sites across the US and Europe. In Phase 2, CYB003 showed a 75% remission rate from depression four months after two 16mg doses. Cybin expects to report 12-month efficacy data from Phase 2 in Q4 this year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:37 am

XOMA

XOMA Corporation reported its Q2 2024 financial results, with GAAP EPS of $0.84, significantly beating the estimated loss of $(0.27). Additionally, sales reached $11.086 million, surpassing the $8.377 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:36 am

MSGS

Madison Square Garden (MSGS) reported Q4 2024 GAAP EPS of $1.06, significantly beating the estimate of $0.45.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:33 am

PSTV

Plus Therapeutics announced that its CNSide Leptomeningeal Metastases FORSEE Trial met key primary and secondary endpoints. The trial demonstrated that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target. The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:32 am

VRPX

Virpax Pharmaceuticals reported a Q2 2024 GAAP EPS of $(1.75), which is significantly lower than the $(0.61) estimate. This discrepancy may impact investor sentiment negatively.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:32 am

MSGS

Madison Square Garden reported Q4 sales of $227.251 million, significantly beating the estimate of $167.571 million.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:31 am

IHS

IHS Holding (NYSE:IHS) reported Q2 2024 GAAP EPS of $(0.36), missing the $0.15 estimate by 340%. Sales of $435.377M beat the $428.302M estimate but were down 20.29% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:30 am

PRTG

Portage Biotech has approved a reverse stock split of 1-for-20, effective August 15.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:27 am

NIU

Niu Technologies (NASDAQ:NIU) has returned to growth after a challenging year, opening 300 new stores in the first half of the year. Analysts are increasingly bullish, with all three polled by Yahoo Finance rating the company as a 'buy' or 'strong buy'. Despite a 1.6% drop in share price following the latest report, the company forecasts significant growth in the third quarter.

Portfolio Pulse from The Bamboo Works

August 13, 2024 | 11:27 am

CORZ

Core Scientific plans to offer $350 million of convertible senior notes due 2029 in a private offering. This move is likely aimed at raising capital for future growth and operational needs.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:26 am